[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053272":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":39,"centralContacts":43,"locations":49,"responsibleParty":115,"collaborators":34,"id":117,"slug":34,"hasResults":118,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":34,"eligibilityCriteria":122,"healthyVolunteers":118,"sex":123,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":34,"studyType":129,"phases":130,"briefSummary":132,"conditions":133,"keywords":34,"overallStatus":52,"whyStopped":34,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":144},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,14,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Panel A MK-1403 + additive coformulation dose 1","EXPERIMENTAL","Participants will receive MK-1403 + additive coformulation dose 1 orally once daily.",[13],"Drug: MK-1403 + additive coformulation",{"label":15,"type":16,"description":17,"interventionNames":18},"Panel A Placebo + additive coformulation dose 1","PLACEBO_COMPARATOR","Participants will receive Placebo + additive coformulation dose 1 orally once daily.",[19],"Drug: Placebo + additive coformulation",{"label":21,"type":10,"description":22,"interventionNames":23},"Panel B MK-1403 + additive coformulation dose 2","Participants will receive MK-1403 + additive coformulation dose 2 orally once daily",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"Panel B Placebo + additive coformulation dose 2","Participants will receive Placebo + additive coformulation dose 2 orally once daily",[19],[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","MK-1403 + additive coformulation","MK-1403 + additive coformulation is a co-formulated product of MK-1403 administered orally.",[9,21],null,{"type":30,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"Placebo + additive coformulation","Placebo + additive coformulation is a co-formulated product of placebo administered orally.",[15,25],[40],{"name":41,"affiliation":5,"role":42},"Medical Director","STUDY_DIRECTOR",[44],{"name":45,"role":46,"phone":47,"phoneExt":34,"email":48},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[50,67,79,92,104],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Anaheim Clinical Trials ( Site 0006)","RECRUITING","Anaheim","California","92801","United States",{"type":58,"coordinates":59},"Point",[60,61],-117.9145,33.83529,{"lat":61,"lon":60},[64],{"name":65,"role":46,"phone":66,"phoneExt":34,"email":34},"Study Coordinator","714-774-7777",{"facility":68,"status":52,"city":69,"state":54,"zip":70,"country":56,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"ProSciento Inc. ( Site 0001)","Chula Vista","91911",{"type":58,"coordinates":72},[73,74],-117.0842,32.64005,{"lat":74,"lon":73},[77],{"name":65,"role":46,"phone":78,"phoneExt":34,"email":34},"619-427-1300",{"facility":80,"status":52,"city":81,"state":82,"zip":83,"country":56,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Advanced Pharma CR, LLC ( Site 0003)","Miami","Florida","33147",{"type":58,"coordinates":85},[86,87],-80.19366,25.77427,{"lat":87,"lon":86},[90],{"name":65,"role":46,"phone":91,"phoneExt":34,"email":34},"305-220-2727",{"facility":93,"status":52,"city":94,"state":82,"zip":95,"country":56,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"QPS-MRA, LLC ( Site 0004)","South Miami","33143",{"type":58,"coordinates":97},[98,99],-80.29338,25.7076,{"lat":99,"lon":98},[102],{"name":65,"role":46,"phone":103,"phoneExt":34,"email":34},"305-722-0970",{"facility":105,"status":106,"city":107,"state":108,"zip":109,"country":56,"cosmosGeoPoint":110,"geoPoint":114,"contacts":34},"Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0005)","COMPLETED","Springfield","Missouri","65802",{"type":58,"coordinates":111},[112,113],-93.29824,37.21533,{"lat":113,"lon":112},{"type":116,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100053272",false,"NCT07242469","A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)","A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1403 in Participants With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Has a confirmed diagnosis of Type 2 diabetes mellitus (T2DM)\n* Has body mass index (BMI) between 18 and 40 kg\u002Fm\\^2, inclusive\n\nExclusion Criteria:\n\n* Has Type 1 diabetes mellitus or secondary types of diabetes\n* Has a history of congestive heart failure (New York Heart Association \\[NYHA\\] Class 3 or 4)\n* Has history of myocardial infarction, uncontrolled arrhythmias, cardiac revascularization, angina, unstable peripheral arterial disease and\u002For stroke\n* Has history of cancer (malignancy)\n* Has positive test(s) for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or human immunodeficiency virus (HIV)\n* Has a history of gastrointestinal (GI) disease which might affect food and drug absorption, or has had gastric bypass or similar surgery","ALL","18 Years","75 Years",{"count":127,"type":128},52,"ESTIMATED","INTERVENTIONAL",[131],"PHASE1","The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-1403. The study will also measure what happens to MK-1403 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive protein (hsCRP) in a person's blood.",[134],"Diabetes Mellitus, Type 2","2026-07-10",{"date":137,"type":138},"2026-07-13","ACTUAL",{"date":140,"type":138},"2025-12-22",{"date":142,"type":128},"2026-08-28",{"name":5,"class":6},5]